INTERVIEW: Humanizing Antibodies And Inventing Humira; Greg Winter's Story So Far
Executive Summary
Biochemist Greg Winter has scientifically contributed to some of the pharmaceutical industry's biggest commercial and therapeutic success stories. He tells Scrip how he feels about being labelled a pioneer and why he is still wary of the boardroom.
You may also be interested in...
INTERVIEW: Finding Stars And Staying Independent, Biotech Veteran David Chiswell's Five Year Plan
David Chiswell has worked tirelessly to build up the British biotech industry for over 30 years. Now, as CEO of Kymab, he is looking to the future of the industry and how to find the stars of the future.
A Life In Genes: Scrip Award Winner Sir Gregory Winter's Speech
The 2015 Scrip Lifetime Achievement Award was given to Sir Gregory Winter, Master of Trinity College, Cambridge (UK). Founder of Cambridge Antibody Technology (acquired by AstraZeneca), Domantis (acquired by GlaxoSmithKline) and Bicycle Therapeutics, he is best known for his pioneering research into humanizing antibodies. His findings led to the development of the first human antibody, Humira (adalimumab), until very recently the world's top-selling drug.
Coming Of Age: Pharma’s Influencer Marketing Matures
Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.